Last reviewed · How we verify
Nicotine higher dose
At a glance
| Generic name | Nicotine higher dose |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Effect of Product Characteristics on the Abuse Liability of Nicotine Pouches (NA)
- ACT Therapy for HF Migraine (NA)
- Reward Sensitivity and Pharmacotherapy for Smoking Cessation (PHASE4)
- Varenicline and Combined NRT for Smoking Cessation (PHASE4)
- Study of the Effectiveness of a Virtual Reality Treatment in the Management of Smoking Cessation (NA)
- Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment (PHASE2)
- Effect of Perioperative High-dose Transdermal Nicotine Patch on Pain Sensitivity Among Male Abstinent Tobacco Smokers Undergoing Thoracic Surgery: A Randomized Controlled Pilot Study (NA)
- Effect of Cannabis on Cigarette Use Behavior (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nicotine higher dose CI brief — competitive landscape report
- Nicotine higher dose updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI